Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke (original) (raw)

• Thom, T. et al. Heart disease and stroke statistics—2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 113, e85–e151 (2006).
  PubMed Google Scholar
• Hou, S.T. & MacManus, J.P. Molecular mechanisms of cerebral ischemia-induced neuronal death. Int. Rev. Cytol. 221, 93–148 (2002).
  Article CAS Google Scholar
• Marler, J.R. & Goldstein, L.B. Medicine. Stroke—tPA and the clinic. Science 301, 1677 (2003).
  Article CAS Google Scholar
• Tsirka, S.E., Gualandris, A., Amaral, D.G. & Strickland, S. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 377, 340–344 (1995).
  Article CAS Google Scholar
• Tsirka, S.E., Rogove, A.D., Bugge, T.H., Degen, J.L. & Strickland, S. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J. Neurosci. 17, 543–552 (1997).
  Article CAS Google Scholar
• Wang, Y.F. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat. Med. 4, 228–231 (1998).
  Article CAS Google Scholar
• Nagai, N., De Mol, M., Lijnen, H.R., Carmeliet, P. & Collen, D. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 99, 2440–2444 (1999).
  Article CAS Google Scholar
• Yepes, M. et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 96, 569–576 (2000).
  CAS PubMed Google Scholar
• Nicole, O. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat. Med. 7, 59–64 (2001).
  Article CAS Google Scholar
• Cinelli, P. et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol. Cell. Neurosci. 18, 443–457 (2001).
  Article CAS Google Scholar
• Yepes, M. et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J. Clin. Invest. 109, 1571–1578 (2002).
  Article CAS Google Scholar
• Pawlak, R., Melchor, J.P., Matys, T., Skrzypiec, A.E. & Strickland, S. Ethanol-withdrawal seizures are controlled by tissue plasminogen activator via modulation of NR2B-containing NMDA receptors. Proc. Natl. Acad. Sci. USA 102, 443–448 (2005).
  Article CAS Google Scholar
• Tabrizi, P. et al. Tissue plasminogen activator (tPA) deficiency exacerbates cerebrovascular fibrin deposition and brain injury in a murine stroke model: studies in tPA-deficient mice and wild-type mice on a matched genetic background. Arterioscler. Thromb. Vasc. Biol. 19, 2801–2806 (1999).
  Article CAS Google Scholar
• Zivin, J.A., Fisher, M., DeGirolami, U., Hemenway, C.C. & Stashak, J.A. Tissue plasminogen activator reduces neurological damage after cerebral embolism. Science 230, 1289–1292 (1985).
  Article CAS Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N. Engl. J. Med. 333, 1581–1587 (1995).
• Zhang, Z. et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 106, 740–745 (2002).
  Article CAS Google Scholar
• Yepes, M. et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor–related protein. J. Clin. Invest. 112, 1533–1540 (2003).
  Article CAS Google Scholar
• Herz, J. LRP: a bright beacon at the blood-brain barrier. J. Clin. Invest. 112, 1483–1485 (2003).
  Article CAS Google Scholar
• Wang, X. et al. Lipoprotein receptor–mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat. Med. 9, 1313–1317 (2003).
  Article CAS Google Scholar
• Fredriksson, L., Li, H., Fieber, C., Li, X. & Eriksson, U. Tissue plasminogen activator is a potent activator of PDGF-CC. EMBO J. 23, 3793–3802 (2004).
  Article CAS Google Scholar
• Li, X. et al. PDGF-C is a new protease-activated ligand for the PDGF-α receptor. Nat. Cell Biol. 2, 302–309 (2000).
  Article CAS Google Scholar
• Fredriksson, L., Ehnman, M., Fieber, C. & Eriksson, U. Structural requirements for activation of latent platelet-derived growth factor CC by tissue plasminogen activator. J. Biol. Chem. 280, 26856–26862 (2005).
  Article CAS Google Scholar
• Hart, C.E. et al. Two classes of PDGF receptor recognize different isoforms of PDGF. Science 240, 1529–1531 (1988).
  Article CAS Google Scholar
• Polavarapu, R. et al. Tissue-type plasminogen activator–mediated shedding of astrocytic low-density lipoprotein receptor–related protein increases the permeability of the neurovascular unit. Blood 109, 3270–3278 (2007).
  Article CAS Google Scholar
• Willnow, T.E. & Herz, J. Genetic deficiency in low density lipoprotein receptor–related protein confers cellular resistance to Pseudomonas exotoxin A. Evidence that this protein is required for uptake and degradation of multiple ligands. J. Cell Sci. 107, 719–726 (1994).
  CAS PubMed Google Scholar
• Yu, H. et al. Control elements between −9.5 and −3.0 kb in the human tissue-type plasminogen activator gene promoter direct spatial and inducible expression to the murine brain. Eur. J. Neurosci. 14, 799–808 (2001).
  Article CAS Google Scholar
• Hamilton, T.G., Klinghoffer, R.A., Corrin, P.D. & Soriano, P. Evolutionary divergence of platelet-derived growth factor α receptor signaling mechanisms. Mol. Cell. Biol. 23, 4013–4025 (2003).
  Article CAS Google Scholar
• Ding, H. et al. A specific requirement for PDGF-C in palate formation and PDGFR-α signaling. Nat. Genet. 36, 1111–1116 (2004).
  Article CAS Google Scholar
• Wolf, B.B., Lopes, M.B., VandenBerg, S.R. & Gonias, S.L. Characterization and immunohistochemical localization of α 2-macroglobulin receptor (low-density lipoprotein receptor–related protein) in human brain. Am. J. Pathol. 141, 37–42 (1992).
  CAS PubMed PubMed Central Google Scholar
• Nagai, N. et al. Tissue-type plasminogen activator has paradoxical roles in focal cerebral ischemic injury by thrombotic middle cerebral artery occlusion with mild or severe photochemical damage in mice. J. Cereb. Blood Flow Metab. 22, 648–651 (2002).
  Article CAS Google Scholar
• Nagai, N., Suzuki, Y., Van, H.B., Lijnen, H.R. & Collen, D. Effects of plasminogen activator inhibitor-1 on ischemic brain injury in permanent and thrombotic middle cerebral artery occlusion models in mice. J. Thromb. Haemost. 3, 1379–1384 (2005).
  Article CAS Google Scholar
• Capdeville, R., Buchdunger, E., Zimmermann, J. & Matter, A. Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat. Rev. Drug Discov. 1, 493–502 (2002).
  Article CAS Google Scholar
• The National Institute of Neurological Disorders and Stroke t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 28, 2109–2118 (1997).
• Larrue, V., von Kummer, R.R., Muller, A. & Bluhmki, E. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: a secondary analysis of the European-Australasian Acute Stroke Study (ECASS II). Stroke 32, 438–441 (2001).
  Article CAS Google Scholar
• Thomalla, G. et al. Two tales: hemorrhagic transformation but not parenchymal hemorrhage after thrombolysis is related to severity and duration of ischemia: MRI study of acute stroke patients treated with intravenous tissue plasminogen activator within 6 hours. Stroke 38, 313–318 (2007).
  Article Google Scholar
• Vora, N.A. et al. Factors predicting hemorrhagic complications after multimodal reperfusion therapy for acute ischemic stroke. AJNR Am. J. Neuroradiol. 28, 1391–1394 (2007).
  Article CAS Google Scholar
• Yepes, M. & Lawrence, D.A. New functions for an old enzyme: nonhemostatic roles for tissue-type plasminogen activator in the central nervous system. Exp. Biol. Med. (Maywood) 229, 1097–1104 (2004).
  Article CAS Google Scholar
• Yepes, M. & Lawrence, D.A. Tissue-type plasminogen activator and neuroserpin: a well balanced act in the nervous system? Trends Cardiovasc. Med. 14, 173–180 (2004).
  Article CAS Google Scholar
• Zhuo, M. et al. Role of tissue plasminogen activator receptor LRP in hippocampal long- term potentiation. J. Neurosci. 20, 542–549 (2000).
  Article CAS Google Scholar
• Hao, Z. et al. New transgenic evidence for a system of sympathetic axons able to express tissue plasminogen activator (t-PA) within arterial/arteriolar walls. Blood 108, 200–202 (2006).
  Article CAS Google Scholar
• Gualandris, A., Jones, T.E., Strickland, S. & Tsirka, S.E. Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator. J. Neurosci. 16, 2220–2225 (1996).
  Article CAS Google Scholar
• Breedveld, P. et al. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and _P_-glycoprotein inhibitors to enable the brain penetration of imatinib in patients. Cancer Res. 65, 2577–2582 (2005).
  Article CAS Google Scholar
• Melchor, J.P. & Strickland, S. Tissue plasminogen activator in central nervous system physiology and pathology. Thromb. Haemost. 93, 655–660 (2005).
  Article CAS Google Scholar
• Ponten, A. et al. Transgenic overexpression of platelet-derived growth factor-C in the mouse heart induces cardiac fibrosis, hypertrophy, and dilated cardiomyopathy. Am. J. Pathol. 163, 673–682 (2003).
  Article CAS Google Scholar
• McMahon, G.A. et al. Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J. Biol. Chem. 276, 33964–33968 (2001).
  Article CAS Google Scholar